Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter, Oasmia Ink Apealea Commercial Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Baxter, Oasmia Ink Apealea Commercial Mfg. Pact

Apealea will be manufactured at Baxter’s cytotoxic manufacturing site in Germany

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oasmia Pharmaceutical AB signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology transfer to Baxter is complete and manufacturing is planned to commence soon. Terms of the agreement were not disclosed.

Apealea will be manufactured at Baxter’s manufacturing site in Halle/Westfalen, Germany, a facility for cytotoxic contract manufacturing. Oasmia plans to shift its manufacturing at its site in Uppsala to focus on its other products, Doxophos and Docecal.

“This is an important step for Oasmia’s future growth and essential for our commercial success. We see this as an important step to accelerate the launch of Apealea and our other product candidates. Baxter is a very strong partner and enables us to meet the global demand of Apealea,” said Julian Aleksov, executive chairman of Oasmia Pharmaceutical AB.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics